title: Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource.
abstract: Since its inception in the mid-1980s, the General Practice Research Database (GPRD) has undergone many changes but remains the largest validated and most utilised primary care database in the UK. Its use in pharmacoepidemiology stretches back many years with now over 800 original research papers. Administered by the Medicines and Healthcare products Regulatory Agency since 2001, the last 5 years have seen a rebuild of the database processing system enhancing access to the data, and a concomitant push towards broadening the applications of the database. New methodologies including real-world harm-benefit assessment, pharmacogenetic studies and pragmatic randomised controlled trials within the database are being implemented. A substantive and unique linkage program (using a trusted third party) has enabled access to secondary care data and disease-specific registry data as well as socio-economic data and death registration data. The utility of anonymised free text accessed in a safe and appropriate manner is being explored using simple and more complex techniques such as natural language processing.
authors.forename: Tim
authors.initials: T
authors.lastname: Williams
authors.forename: Tjeerd
authors.initials: T
authors.lastname: van Staa
authors.forename: Shivani
authors.initials: S
authors.lastname: Puri
authors.forename: Susan
authors.initials: S
authors.lastname: Eaton
keywords: database; pharmacoepidemiology; primary care
references.citation: PLoS Med. 2009 Dec;6(12):e1000194
references.pmid: 19997499
references.citation: Trials. 2011 May 10;12:115
references.pmid: 21569237
references.citation: Int J Med Inform. 2004 Jun 15;73(5):443-53
references.pmid: 15171985
references.citation: Inform Prim Care. 2004;12(3):171-7
references.pmid: 15606990
references.citation: Br J Gen Pract. 2010 Mar;60(572):e128-36
references.pmid: 20202356
references.citation: Osteoporos Int. 2006 Dec;17(12):1808-14
references.pmid: 16932873
references.citation: PLoS Med. 2009 Sep;6(9):e1000154
references.pmid: 19787025
references.citation: J Public Health Med. 1999 Sep;21(3):299-304
references.pmid: 10528957
references.citation: Pharmacoepidemiol Drug Saf. 2001 Aug-Sep;10(5):379-83
references.pmid: 11802580
references.citation: Drug Saf. 2004;27(12):871-81
references.pmid: 15366975
references.citation: CMAJ. 2011 Sep 6;183(12):E809-16
references.pmid: 21810950
references.citation: Int J Epidemiol. 2008 Apr;37(2):405-13
references.pmid: 18263647
references.citation: J Intern Med. 2008 Nov;264(5):481-92
references.pmid: 18624902
references.citation: Eur Heart J. 2011 Oct;32(19):2376-86
references.pmid: 21875855
references.citation: QJM. 1998 Jun;91(6):445-52
references.pmid: 9709463
references.citation: Lancet. 1997 Oct 11;350(9084):1097-9
references.pmid: 10213569
references.citation: BMC Public Health. 2011 Feb 07;11:86
references.pmid: 21299872
references.citation: Inform Prim Care. 2004;12(1):49-50
references.pmid: 15140353
references.citation: Fam Pract. 2006 Apr;23(2):253-63
references.pmid: 16368704
references.citation: PLoS One. 2009 Sep 24;4(9):e7168
references.pmid: 19777060
references.citation: Br J Clin Pharmacol. 2010 Jan;69(1):4-14
references.pmid: 20078607